Who Paid My Doc
Maribel Lopez
General Practice Palm Bay, FL Medical Doctor
NPI 1649349697 CMS profile 2782733
590 Malabar Rd Se Ste 1, Palm Bay, FL 32907
General payments
$690
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Maribel Lopez of Palm Bay, FL is reported in the CMS Open Payments database as having received $690 across 36 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 74th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $187 | 9 | |
| 2024 | General | $101 | 4 | |
| 2023 | General | $280 | 15 | |
| 2022 | General | $121 | 8 |
Beside peers
- Maribel Lopez
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Maribel Lopez were reported at $187. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Maribel Lopez | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $0 | $93 | $30–$272 | $132 |
| 2022 | $121 | $103 | $36–$279 | $149 |
| 2023 | $280 | $106 | $34–$276 | $160 |
| 2024 | $101 | $114 | $39–$290 | $164 |
| 2025 | $187 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 124 drugsPart D claims
7,155
Drug cost
$321,744
Branded share of claims
15%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Januvia Sitagliptin Phosphate | Brand | 37 | $59,480 | |
| Eliquis Apixaban | Brand | 40 | $42,887 | |
| Jardiance Empagliflozin | Brand | 20 | $33,386 | |
| Farxiga Dapagliflozin Propanediol | Brand | 27 | $26,991 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 12 | $19,433 | |
| Trulicity Dulaglutide | Brand | 15 | $17,215 | |
| Xarelto Rivaroxaban | Brand | 13 | $13,396 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 84 | $8,432 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 21 | $7,800 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 13 | $7,320 |
The 10 drugs with the highest cost, of 124 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 23 billing codesPaid by Medicare
$4,964
Medicare patients
19
Services billed
236
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VRAYLAR |
|
$21 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
36 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other General Practice in Florida
Caley Castelein
General Practice · Miami Beach, FL
Robert Althar
General Practice · Pensacola, FL
Florencia Ziemke
General Practice · West Palm Beach, FL
Ausberto Hidalgo
General Practice · Pembroke Pines, FL
Ernesto Lamadrid
General Practice · Gainesville, FL
Idalia Acosta
General Practice · Miami, FL
Related records
General Practice in Florida
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.